Bifidobacterium lactis ： Chronic Constipation
BDose-dependently reduces whole gut transit time (WGTT). Higher dose (17.2 billion CFU) showed 31% reduction in WGTT. Also reduces functional GI symptoms.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbifidobacterium\u002Dlactis\u0026condition\u003Dconstipation';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
Dose-dependently reduces whole gut transit time (WGTT). Higher dose (17.2 billion CFU) showed 31% reduction in WGTT. Also reduces functional GI symptoms.
Key Study Findings
Randomized Controlled Trial
8 weeks
Double-blind
Effect of an 8-Week Bifidobacterium lactis HN019 Supplementation on Functional Constipation: A Multi-Center, Triple-Blind, Randomized, …
Dose: None
vs: Placebo
Outcome: Complete spontaneous bowel movements (CSBMs)
効果: None
None
対象集団: Adults with functional constipation (Rome III)
Randomized Controlled Trial
n=67
4 weeks
Double-blind
Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with …
Dose: None
vs: Placebo
Outcome: Weekly spontaneous bowel movements
効果: 4.94 vs 3.00 (P<0.001)
P<0.001
対象集団: Older adults >=60 with functional constipation (Rome IV)
Randomized Controlled Trial
n=35
12 weeks
Double-blind
Multistrain Probiotics Plus Vitamin D Improve Gut Barrier Function and Gut Microbiota Composition in Irritable …
Dose: None
vs: Placebo
Outcome: Gut barrier function (zonulin levels)
効果: Zonulin -19.5 ng/mL at week 16
p=0.0002 wk16; p=0.0053 grp
対象集団: IBS without constipation patients
Review
An update on probiotics in paediatrics.
Dose: None
vs: None
Outcome: GI disorder outcomes in paediatrics
効果: None
None
対象集団: Paediatric patients with GI disorders
In Vitro
n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL
vs: IBS supernatants without probiotic
Outcome: Caco-2 paracellular permeability
効果: None
<0.001
対象集団: IBS patients (28) and asymptomatic controls (7)
Randomized Controlled Trial
n=128
2 weeks
Double-blind
Probiotics and Fever Duration in Children With Upper Respiratory Tract Infections: A Randomized Clinical Trial.
Dose: 0.5 mL daily for 14 days
vs: Placebo
Outcome: Fever duration (days)
効果: RR 0.64 (95% CI 0.51-0.80)
None
対象集団: Children 28 days-4 years with fever and URTI
Key Statistics
4
研究数
600
参加者数
↑
Positive
B
グレード
Referenced Papers
JAMA network open
2025
13 件の引用
Nutrients
2025
7 件の引用
International journal of …
2025
4 件の引用
Molecular nutrition & …
2025
2 件の引用
The journal of …
2025
Current opinion in …
2025
JAMA network open
2024
9 件の引用
European journal of …
2024
9 件の引用
Gut microbes
2023
143 件の引用
Journal of clinical …
2023
9 件の引用
Clinical nutrition (Edinburgh, …
2022
42 件の引用
Frontiers in nutrition
2022
24 件の引用
Frontiers in nutrition
2022
22 件の引用
Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models.
Other
PloS one
2022
21 件の引用
Medicine
2022
14 件の引用
Frontiers in microbiology
2022
4 件の引用
Medicine
2021
8 件の引用
Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults.
Meta-Analysis
Clinical nutrition (Edinburgh, …
2020
94 件の引用
Beneficial microbes
2020
22 件の引用
Arquivos de gastroenterologia
2020
7 件の引用
Alimentary pharmacology & …
2019
59 件の引用
Probiotics and antimicrobial …
2019
43 件の引用
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 件の引用
Nutrients
2018
28 件の引用
The Turkish journal …
2017
29 件の引用
Pediatric gastroenterology, hepatology …
2017
27 件の引用
Frontiers in neuroscience
2017
14 件の引用
Korean journal for …
2017
7 件の引用
The Turkish journal …
2016
63 件の引用
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 件の引用
The American journal …
2014
284 件の引用
Nutrition journal
2014
75 件の引用
Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials.
Meta-Analysis
World journal of …
2013
111 件の引用
Arquivos de gastroenterologia
2013
49 件の引用
Georgian medical news
2013
World journal of …
2012
55 件の引用
Is a multispecies probiotic mixture effective in constipation during pregnancy? 'A pilot study'.
Other
Nutrition journal
2012
51 件の引用
Scandinavian journal of …
2011
187 件の引用
Journal of clinical …
2011
163 件の引用
Pediatrics
2011
101 件の引用
Systematic review of randomised controlled trials: probiotics for functional constipation.
Systematic Review
World journal of …
2010
276 件の引用
Alimentary pharmacology & …
2009
333 件の引用
BMC pediatrics
2009
46 件の引用
Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women.
RCT
World journal of …
2008
163 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1-10 billion CFU/day
- immunesupport:
- 5-10 billion CFU/day
- constipationsupport:
- 17.2 billion CFU/day (HN019 strain, optimal dose)
上限量： Well-tolerated up to 17.2 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | 8 weeks | Neutral | -- |
| None | 4 weeks | Positive | 67 |
| None | 12 weeks | Positive | 35 |
| None | -- | Positive | -- |
| 1e6 CFU/mL | -- | Positive | 35 |
| 0.5 mL daily for 14 days | 2 weeks | Positive | 128 |
| None | 2 weeks | Negative | 117 |
| 10 g | 4 weeks | Positive | -- |
推奨摂取タイミング： With or without food; morning dosing may be optimal for transit effects
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional abdominal discomfort
- ⚠ Rare loose stools
- ⚠ Very rare: bacteremia in immunocompromised individuals
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (use with caution in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 17.2 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Bifidobacterium lactis help with Chronic Constipation?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium lactis may support Chronic Constipation management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium lactis should I take for Chronic Constipation?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium lactis?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium lactis and Chronic Constipation?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Chronic Constipation
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。